Difference between revisions of "Ber-EP4"
Jump to navigation
Jump to search
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Ber-EP4''' is a commonly available [[immunostain]]. | '''Ber-EP4''' is a commonly available [[immunostain]]. It is directed against EpCam.<ref name=pmid24179394>{{Cite journal | last1 = Dasgeb | first1 = B. | last2 = Mohammadi | first2 = TM. | last3 = Mehregan | first3 = DR. | title = Use of Ber-EP4 and Epithelial Specific Antigen to Differentiate Clinical Simulators of Basal Cell Carcinoma. | journal = Biomark Cancer | volume = 5 | issue = | pages = 7-11 | month = | year = 2013 | doi = 10.4137/BIC.S11856 | PMID = 24179394 }}</ref> | ||
==Positive== | ==Positive== | ||
*[[Basal cell carcinoma]]. | *[[Basal cell carcinoma]]. | ||
*[[Lung adenocarcinoma]] (55 of 59 cases<ref name=pmid9426522>{{Cite journal | last1 = Ordóñez | first1 = NG. | title = Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. | journal = Am J Clin Pathol | volume = 109 | issue = 1 | pages = 85-9 | month = Jan | year = 1998 | doi = | PMID = 9426522 }}</ref>). | *[[Lung adenocarcinoma]] (55 positive of 59 cases<ref name=pmid9426522>{{Cite journal | last1 = Ordóñez | first1 = NG. | title = Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. | journal = Am J Clin Pathol | volume = 109 | issue = 1 | pages = 85-9 | month = Jan | year = 1998 | doi = | PMID = 9426522 }}</ref>). | ||
==Negative== | ==Negative== | ||
*[[Squamous cell carcinoma of the skin]]. | *[[Squamous cell carcinoma of the skin]].<ref name=pmid19187107>{{Cite journal | last1 = Yu | first1 = L. | last2 = Galan | first2 = A. | last3 = McNiff | first3 = JM. | title = Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. | journal = J Cutan Pathol | volume = 36 | issue = 10 | pages = 1074-176 | month = Oct | year = 2009 | doi = 10.1111/j.1600-0560.2008.01223.x | PMID = 19187107 }}</ref> | ||
*[[Malignant mesothelioma]] (18 of 70 cases<ref name=pmid9426522/>). | *[[Malignant mesothelioma]] (18 positive of 70 cases<ref name=pmid9426522/>). | ||
*[[Microcystic adnexal carcinoma]].<ref name=pmid23398472 >{{Cite journal | last1 = Sellheyer | first1 = K. | last2 = Nelson | first2 = P. | last3 = Kutzner | first3 = H. | last4 = Patel | first4 = RM. | title = The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. | journal = J Cutan Pathol | volume = 40 | issue = 4 | pages = 363-70 | month = Apr | year = 2013 | doi = 10.1111/cup.12085 | PMID = 23398472 }}</ref> | *[[Microcystic adnexal carcinoma]].<ref name=pmid23398472 >{{Cite journal | last1 = Sellheyer | first1 = K. | last2 = Nelson | first2 = P. | last3 = Kutzner | first3 = H. | last4 = Patel | first4 = RM. | title = The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. | journal = J Cutan Pathol | volume = 40 | issue = 4 | pages = 363-70 | month = Apr | year = 2013 | doi = 10.1111/cup.12085 | PMID = 23398472 }}</ref> | ||
==See also== | ==See also== | ||
*[[Immunohistochemistry]]. | *[[Immunohistochemistry]]. | ||
*[[MOC31]]. | |||
==References== | ==References== | ||
Latest revision as of 17:05, 15 May 2016
Ber-EP4 is a commonly available immunostain. It is directed against EpCam.[1]
Positive
- Basal cell carcinoma.
- Lung adenocarcinoma (55 positive of 59 cases[2]).
Negative
- Squamous cell carcinoma of the skin.[3]
- Malignant mesothelioma (18 positive of 70 cases[2]).
- Microcystic adnexal carcinoma.[4]
See also
References
- ↑ Dasgeb, B.; Mohammadi, TM.; Mehregan, DR. (2013). "Use of Ber-EP4 and Epithelial Specific Antigen to Differentiate Clinical Simulators of Basal Cell Carcinoma.". Biomark Cancer 5: 7-11. doi:10.4137/BIC.S11856. PMID 24179394.
- ↑ 2.0 2.1 Ordóñez, NG. (Jan 1998). "Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.". Am J Clin Pathol 109 (1): 85-9. PMID 9426522.
- ↑ Yu, L.; Galan, A.; McNiff, JM. (Oct 2009). "Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma.". J Cutan Pathol 36 (10): 1074-176. doi:10.1111/j.1600-0560.2008.01223.x. PMID 19187107.
- ↑ Sellheyer, K.; Nelson, P.; Kutzner, H.; Patel, RM. (Apr 2013). "The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers.". J Cutan Pathol 40 (4): 363-70. doi:10.1111/cup.12085. PMID 23398472.